We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Understanding tumor lysis syndrome.
- Authors
Zafrani, Lara; Canet, Emmanuel; Darmon, Michael
- Abstract
Tumor lysis syndrome (TLS) is a life-threatening condition in patients with extensive and chemosensitive malignancies. Despite routine urate oxidase therapy, TLS may develop in up to two-thirds of high-risk patients, leading to AKI in half of them [[2]]. It is the drug of choice for prophylaxis in patients with low/intermediate risk of TLS, but it may be less effective than rasburicase in patients with hyperuricemia and already formed urate crystals [[8], [11]]. These same guidelines recommend the use of rasburicase in established TLS and for prevention in high-risk patients and intermediate-risk patients with hyperuricemia [[9]].
- Subjects
TUMOR lysis syndrome; CHRONIC lymphocytic leukemia; LEUKOCYTE count; CLUSTER randomized controlled trials
- Publication
Intensive Care Medicine, 2019, Vol 45, Issue 11, p1608
- ISSN
0342-4642
- Publication type
journal article
- DOI
10.1007/s00134-019-05768-x